Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Artemisinin,Curcumin,Boswellia Serrata

            Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Malta Enerprises

            Deal Size: $3.7 million Upfront Cash: $3.7 million

            Deal Type: Funding December 22, 2020

            Details:

            The Malta facility will create a European manufacturing hub for ArtemiCTM with the ability to scale production to meet expected growing demand following positive clinical trial results.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Artemisinin,Curcumin,Frankincense

            Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 07, 2020

            Details:

            Interim Results reported to date demonstrate ArtemiCTM has met all primary end points for safety and efficacy, and FDA primary endpoint of sustained clinical recovery of COVID-19 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eftilagimod Alpha

            Therapeutic Area: Infections and Infectious Diseases Product Name: IMP321

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: University Hospital Pilsen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 23, 2020

            Details:

            Immutep will provide Efti at no cost to the University Hospital Pilsen which will fund the study. Investigator-initiated, placebo controlled and randomised Phase II study will be conducted evaluating eftilagimod alpha in up to 110 COVID-19 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Artemisinin,Curcumin,Frankincense

            Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 28, 2020

            Details:

            The trial is assessing the safety and efficacy of the natural anti-inflammatory formulation ArtemiCTM, a natural supplement formula based on Artemisinin and Curcumin (along with supporting ingredients Vitamin C and Boswellia serrata) on COVID-19 Patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ArtemiC

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 05, 2020

            Details:

            The double-blind, placebo-controlled Phase II trial will investigate the safety and efficacy of ArtemiC, a natural formulation intended for immune-modulation.